Nanofacturing has accelerated the development of nanotechnologies towards market. It has created of a state-of-the-art, open-access pilot line for the process development and scale-up of nanopharmaceutical manufacture, plus a new sterile Aseptic Manufacturing Suite, are all enabling these innovative medicines to move rapidly towards the market.
Nanomedicines have the potential to provide millions of patient’s worldwide, access to safer and more effective therapies. With the added benefit of treatments being highly targeted, side effects are significantly reduced with healthy tissue being spared. Unmet clinical needs such as orphan oncology applications, anti-viral therapies and central nervous system drugs have the potential to be answered by nanomedicines, ultimately having the potential to save lives.
New processes have enabled reduced manufacturing and raw material costs, which in turn will mean more affordable therapies for patients. Additionally, with the increased knowledge created within each partner organisation the prospect of new jobs and increased revenues in this $140 billion market holds significant economic potential for Europe.
Nanofacturing has developed state of the art techniques to enable a deeper understanding of how GNP’s work within the body. This enhanced knowledge is helping to address the safety and regulatory challenges faced when bringing innovative technologies to various markets.
Nanofacturing has brought together different elements of the nanomedicines supply chain across Europe. From analytical research companies, to process development organisations and pharmaceutical firms, each playing a vital role in getting nanomedicines to market.
Consideration of the environmental impacts of GNP manufacture has meant that new processes are cleaner, more efficient, and more sustainable in addition to producing less waste.